A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70655 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Shiyu Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical College of Shenzhen Second People's Hospital, Anhui Medical University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Acetates, Quinazolines. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shenzhen Key Medical Discipline Construction Fund, Special Support Funds of Shenzhen for Introduced High-Level Medical Team, Shenzhen Bone Marrow Transplantation Public Service Platform.
Abstract (Originalsprache)
Cytomegalovirus (CMV) reactivation is a frequent complication after allogeneic haematopoietic stem cell transplantation (allo‐HSCT), but the timing and duration of letermovir prophylaxis in routine practice remain uncertain. We retrospectively reviewed 97 allo‐HSCT recipients who received letermovir as primary prophylaxis, focusing on CMV‐related outcomes, transplant complications, survival and safety. Letermovir was initiated on day 0 in 31 patients, on day +7 in 44 patients, and on day +14 in 22 patients. The cohort was also stratified by prophylaxis duration, with 51 patients receiving 100‐day prophylaxis and 46 patients receiving 200‐day prophylaxis. Earlier initiation was associated with a lower 100‐day cumulative incidence (CIR) of CMV DNAemia/csCMVi (6.5% vs. 18.2% vs. 36.4%; Gray's test p = 0.008), later first CMV deoxyribonucleic acid (DNA) detection (median 78 vs. 54 vs. 36 days; p = 0.005) and a shorter duration of DNAemia. Compared with the 200‐day group, the 100‐day group had more late CMV reactivation after discontinuation during follow‐up (21.6% vs. 0%; p < 0.001) and numerically lower 1‐year overall survival (80.4% [95% confidence interval (CI), 66.6–88.9] vs. 93.5% [95% CI, 81.1–97.8]; log‐rank p = 0.103), without more severe chronic graft‐versus‐host disease or grade ≥3 drug‐related adverse events. These real‐world findings suggest that both earlier initiation and longer letermovir prophylaxis deserve further evaluation after allo‐HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Clinical College of Shenzhen Second People's Hospital, Anhui Medical University, Shenzhen, Guangdong, China.
ORCID-Profile: Zhihang Su, Xin Du
Förderung
- Shenzhen Key Medical Discipline Construction Fund
- Special Support Funds of Shenzhen for Introduced High-Level Medical Team
- Shenzhen Bone Marrow Transplantation Public Service Platform
Zitieren
APA
Chen, S., Su, Z., Zhang, X., Li, X., & Du, X. (2026). A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. https://doi.org/10.1111/bjh.70655
Vancouver
Chen S, Su Z, Zhang X, Li X, Du X. A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2026. doi:10.1111/bjh.70655
BibTeX
@article{Chen2026,
author = {Chen, Shiyu and Su, Zhihang and Zhang, Xiaohan and Li, Xiaoqing and Du, Xin},
title = {A real‐world study on different initiation times and treatment durations of letermovir for cytomegalovirus prophylaxis after allogeneic haematopoietic stem cell transplantation},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70655}
}
EUVIMED